Proactive Investors - Run By Investors For Investors

Summit Therapeutics advancing its pipeline of innovative antibiotics

Summit Therapeutics PLC’s (NASDAQ:SMMT) (LON:SUMM) Dr Richard Pye updates Proactive London soon after taking their next-generation antibiotic into the final and decisive stage of clinical trials.

The Phase III study of ridinilazole began last month (February).

Summit's also busy developing its pre-clinical candidate for gonorrhoea.

 
Meet Rockfire Resources PLC, Touchstone Exploration Inc, Mkango Resources Ltd and Salt Lake Potash Ltd at our event, London , 20 June 2019. Register here »
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use